Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04194047
Other study ID # RRIRBC
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 1, 2020
Est. completion date September 1, 2022

Study information

Verified date September 2022
Source Università degli Studi di Ferrara
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The renal Doppler resistive index (RRI) is a noninvasive tool that has been used to assess renal perfusion in the intensive care unit (ICU) setting. It is associated with the occurrence of acute kidney injury (AKI). Many parameters have been described as influential on the values of renal RI. Red blood cell (RBC) transfusion were shown to be able to increase renal oxygenation in animal model, whereas crystalloid resuscitation did not. We sought to describe the different effect of crystalloids infusion and RBC transfusion on renal blood flow, as evaluated with doppler ultrasound


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date September 1, 2022
Est. primary completion date September 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Age > 18 and < 90 - Hemoglobin =7 and = 10 g/dl Exclusion Criteria: - Ultrasound RRI evaluation non available - Patients with arrhythmia - Pregnancy - Refusal to give consent - History of renal transplantation - Central venous access in superior vena cava not available Critical active bleeding

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Transfusion
RBC transfusion (1 unit)
Crystalloids infusion
Infusion of 500 ml of balanced crystalloids

Locations

Country Name City State
Italy Università di Ferrara Ferrara

Sponsors (1)

Lead Sponsor Collaborator
Università degli Studi di Ferrara

Country where clinical trial is conducted

Italy, 

References & Publications (2)

Husain-Syed F, Birk HW, Ronco C, Schörmann T, Tello K, Richter MJ, Wilhelm J, Sommer N, Steyerberg E, Bauer P, Walmrath HD, Seeger W, McCullough PA, Gall H, Ghofrani HA. Doppler-Derived Renal Venous Stasis Index in the Prognosis of Right Heart Failure. J Am Heart Assoc. 2019 Nov 5;8(21):e013584. doi: 10.1161/JAHA.119.013584. Epub 2019 Oct 19. — View Citation

Zafrani L, Ergin B, Kapucu A, Ince C. Blood transfusion improves renal oxygenation and renal function in sepsis-induced acute kidney injury in rats. Crit Care. 2016 Dec 20;20(1):406. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other correlation between arterial-venous oxygen differences and changes in renal resistivity index (RRI) after intervention RRI values over>0.70 are considered pathological. Higher values means worse outcome. after 24 hours from intervention
Other correlation between arterial-venous oxygen differences and changes in Renal Venous Stasis Index (RSVI) Under physiological conditions, the index is zero. Higher values means worse outcome. after 24 hours from intervention
Primary Change in renal resistivity index (RRI) after intervention To compare change in RRI after intervention between groups. Values over>0.70 are considered pathological. Higher values means worse outcome. after 60 minute from intervention
Primary Change Renal Venous Stasis Index (RSVI) after intervention To compare change in RSVI after intervention between groups. Under physiological conditions, the index is zero. Higher values means worse outcome. after 60 minute from intervention
Secondary Occurence of AKI Occurence of AKI as defined by Kidney Disease: Improving Global Outcomes (KDIGO) Once a day for 7 days
Secondary Variation in renal resistivity index (RRI) To compare change in RRI after intervention between groupsValues over>0.70 are considered pathological. Higher values means worse outcome. after 24 hours from intervention
Secondary Variation in Renal Venous Stasis Index (RSVI) To compare change in RSVI after intervention between groups. Under physiological conditions, the index is zero. Higher values means worse outcome. after 24 hours from intervention
See also
  Status Clinical Trial Phase
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT03341338 - Genes-in-Action - Hepcidin Regulation of Iron Supplementation
Completed NCT00060398 - Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Not yet recruiting NCT06309641 - Methemoglobinemia Following Intravenous Iron Treatment
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02912494 - A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02912533 - A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT03822884 - Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers Phase 1
Completed NCT02930850 - Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation N/A
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Completed NCT02603250 - Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda N/A
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Completed NCT02310113 - Transfusion and Skeletal Muscle Tissue Oxygenation N/A
Withdrawn NCT01934842 - A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate N/A
Completed NCT01922479 - Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure Phase 4
Completed NCT01693029 - Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Phase 3
Completed NCT01432717 - Study of ACE-536 in Healthy Postmenopausal Women Phase 1
Terminated NCT01535781 - Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced? N/A